Randomized Comparison of Long-term Losartan Versus Propranolol in Lowering Portal Pressure in Cirrhosis
|
|
- Rosa Perkins
- 5 years ago
- Views:
Transcription
1 GASTROENTEROLOGY 2001;121: LIVER, PANCREAS, AND BILIARY TRACT Randomized Comparison of Long-term Losartan Versus Propranolol in Lowering Portal Pressure in Cirrhosis JUAN GONZÁLEZ-ABRALDES,* AGUSTIN ALBILLOS, RAFAEL BAÑARES, LUIS RUIZ DEL ARBOL, EDUARDO MOITINHO,* CLAUDIO RODRÍGUEZ, MONICA GONZÁLEZ, ANGELS ESCORSELL,* JUAN CARLOS GARCÍA-PAGÁN,* and JAUME BOSCH* *Hepatic Hemodynamics Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona; Gastroenterology Unit, Hospital Ramón y Cajal, Universidad de Alcala, Madrid; Hepatic Hemodynamics Laboratory, Liver Unit, Hospital General Universitario Gregorio Marañon, Universidad Complutense, Madrid; and Gastroenterology Unit, Hospital Puerta del Mar, Cádiz, Spain See editorial on page 487. Background & Aims: It has been suggested that losartan, an angiotensin II (A-II) type 1 receptor blocker, may have a pronounced portal pressure reducing effect, far greater than that of propranolol. This randomized controlled trial compared the hemodynamic and renal effects of continued 6-week administration of losartan (n 25) vs. propranolol (n 15) in portal hypertensive patients with cirrhosis treated endoscopically after a variceal bleeding episode. Methods: Hepatic venous pressure gradient (HVPG), systemic hemodynamics, renal function, and vasoactive factors were measured before and at 6 weeks of treatment. Results: Losartan did not reduce HVPG ( 2% 12%, NS) but significantly decreased mean arterial pressure (MAP, 8% 10%, P 0.001). On the contrary, propranolol significantly reduced HVPG ( 10% 11%, P 0.003) and cardiac output ( 16% 12%, P 0.001) but did not modify MAP (2.5% 10%, NS). Losartan increased A-II levels, reduced aldosterone, and decreased glomerular filtration rate (GFR) in Child B patients. Propranolol did not modify renal function. Adverse events related to therapy were mild and similar in both groups. Conclusions: Unlike propranolol, long-term losartan administration does not significantly reduce HVPG in patients with cirrhosis treated after a variceal bleeding episode, and it caused hypotension and reduced GFR in patients with moderate liver failure. Therefore, losartan is not an alternative to propranolol in preventing variceal rebleeding. Many studies have shown that nonselective betablockers, such as propranolol and nadolol, are effective in decreasing portal pressure and the risk of variceal hemorrhage. 1 When the hepatic venous pressure gradient (HVPG) is decreased to 12 mm Hg or below, there is an absolute protection from the risk of bleeding, a significant decrease in the size of varices, and an improvement in the actuarial probability of survival. 2 Even without reaching this target, it has been shown that reductions of the HVPG of more than 20% of baseline values are associated with an extremely low risk of variceal rebleeding. 3,4 Unfortunately such a satisfactory hemodynamic response is achieved in only about one third of the patients. 4 Also, approximately 15% of the patients may have contraindications to beta-blockers or will not tolerate this treatment. This has prompted research of alternative drugs for long-term treatment of portal hypertension. Recently, it has been suggested that the angiotensin II (A-II) type 1 receptor blocker losartan can achieve a marked reduction of HVPG in patients with cirrhosis, without significant adverse effects, 5 suggesting that losartan may be an alternative to beta-blockers in the long-term treatment of portal hypertension. However, previous experiences with other vasodilators 6,7 and with salarasin (a competitive nonselective A-II receptor blocker) 8 suggested that these treatments may cause significant arterial hypotension and adverse renal effects. 9 The present randomized controlled trial was performed to compare the effects of losartan with those of propranolol on splanchnic and systemic hemodynamics and renal function in patients with advanced cirrhosis. Abbreviations used in this paper: A-II, angiotensin II; ALD, aldosterone; CO, cardiac output; ET, endothelin; FHVP, free hepatic venous pressure; GFR, glomerular filtration rate; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure; RAS, renin-angiotensin system; SVR, systemic vascular resistance; WHVP, wedged hepatic venous pressure by the American Gastroenterological Association /01/$35.00 doi: /gast
2 August 2001 LOSARTAN VS. PROPRANOLOL IN PORTAL HYPERTENSION 383 Patients and Methods The study was conducted in patients with cirrhosis who had bled from esophageal varices, recruited from 4 university hospitals in Spain. The final protocol was approved by the Ethical Committee of each participating hospital and the Spanish Ministry of Health and Consumer Affairs. The study was conducted following the principles of the Declaration of Helsinki. Each patient gave written informed consent to participate in the study. Inclusion criteria were: (1) age between 18 and 75 years, (2) positive diagnosis of liver cirrhosis, and (3) variceal bleeding in the course of the previous year treated endoscopically with sclerotherapy or band ligation. The exclusion criteria were: (1) severe liver failure, evaluated by the presence of a serum bilirubin level 5 mg/dl, prothrombin rate 40%, and hepatic encephalopathy, (2) contraindications to beta-blockers (insulin-dependent diabetes mellitus, asthma, chronic obstructive lung diseases, atrioventricular block, heart rate 50 bpm, peripheral arterial disease), (3) serum creatinine 1.6 mg/dl, (4) hyperkaliemia (plasma potassium 5.5 meq/l), (5) systolic blood pressure 90 mm Hg, (6) hepatocellular carcinoma, (7) portal vein thrombosis, and (8) refusal to participate. Presence of ascites and/or treatment with diuretics were not considered exclusion criteria. Protocol Synopsis Patients fulfilling all inclusion criteria and no exclusion criteria were randomized to receive either propranolol or losartan. Losartan was a kind gift from Merck Sharp & Dohme, Spain. The dose was adjusted individually by a trained research nurse on an outpatient basis. For propranolol, starting dose was 20 mg twice daily, which was increased stepwise at 3-day intervals up to a maximum of 160 mg twice daily, if tolerated, as long as heart rate did not decrease below 55 bpm and/or systolic blood pressure below 90 mm Hg. For losartan, the initial dose was 6.25 mg/day, which was increased stepwise at 3-day intervals up to a maximum of 50 mg/day, if tolerated, as long as systolic blood pressure did not decrease below 90 mm Hg. Once the maintenance dose was reached, treatment was maintained for 6 weeks. Patients were seen at 3-week intervals by a physician inadvertent of the allocated treatment. Hemodynamic, renal, and vasoactive neurohumoral systems were evaluated before starting administration of the drug and at the end of the protocol. Sample Size Calculation and Randomization To test whether losartan may increase the number of patients showing a fall in HVPG of 20% of baseline values from the 35% maximal estimate with propranolol 4 to 90% (Schneider et al. reported 98% of patients achieving such a response with losartan 5 ), with alpha 0.05 and beta 0.10, a total of 14 patients in each arm was required. Because information on the effects of propranolol is available from many other published studies, whereas there is very scarce information on losartan, a biased randomization was chosen in a 3:5 ratio. This would provide 15 patients to be treated with propranolol and 25 with losartan. Randomization was computer generated in blocks of 8 patients. The code was kept in consecutively numbered, sealed, opaque envelopes. Every time a patient was introduced into the protocol, the coordinating center (Hospital Clinic) was contacted by fax to be informed of the allocated treatment. A total of 40 patients, 15 in the propranolol group and 25 in the losartan group, were finally included. Procedures Hemodynamic studies. Under fluoroscopic control, a 7 F balloon-tipped catheter (MediTech Cooper Scientific Corp., Watertown, MA) was advanced into the main right hepatic vein to measure wedged and free hepatic venous pressures (WHVP and FHVP, respectively). HVPG was calculated as the difference between WHVP and FHVP. A Swan-Ganz catheter (Abbott Laboratories, IL) was advanced into the pulmonary artery for measurements of cardiopulmonary pressures and cardiac output. A continuous thermal dilution catheter (Webster Laboratories, Inc., Baldwin Park, CA) was placed into the azygos vein for measurement of azygos blood flow (AzBF), according to previously described methods. 10 All measurements were performed at least in duplicate, and permanent tracings were obtained. Tracings were read blindly by the same observer (J.B.). Hepatic blood flow was estimated with the continuous infusion of indocyanine green, as previously described. 11 Mean arterial pressure (MAP) was measured noninvasively with an automatic sphygmomanometer, heart rate was derived from continuous electrocardiogram monitoring, and systemic vascular resistance (SVR) (dyn s 1 cm 5 ) was calculated as (MAP RAP)/CO 80, in which RAP (mm Hg) is the right atrial pressure and CO (L/min) is the cardiac output. Renal Function Renal function was evaluated by measurements of the creatinine clearance, blood urea nitrogen, 24-hour sodium excretion (U Na ), and glomerular filtration rate (GFR) evaluated as the clearance of radiolabeled ethylenediaminetetraacetic acid, as described previously. 7 Hormonal Studies Circulating A-II, aldosterone (ALD), norepinephrine, and endothelin (ET) were measured as previously described. 12,13 Nitrates and nitrites (NOx) were determined by the Griess method as described previously. 14 Statistical Analysis Data are shown in the text as mean SD. Paired Student t test was used to assess the significance of comparisons with baseline within each group and unpaired Student t test for comparisons between groups. Proportional data were analyzed by the Fisher exact test. Significance was established at
3 384 GONZÁLEZ ABRALDES ET AL. GASTROENTEROLOGY Vol. 121, No. 2 Table 1. Baseline Clinical Characteristics of the Patients P All statistics were computed using the SPSS statistical package 9.0 (SPSS, Chicago, IL). Results Losartan (n 23) Propranolol (n 14) P Age NS Sex (M/F) 20/3 11/3 NS Etiology (alcohol/hcv/hbv) 14/8/1 5/8/1 NS Child (A/B/C) 11/12/0 5/7/2 NS Child score (mean SD) NS History of ascites (%) NS Diuretic treatment (%) NS Variceal size 5 mm(%) NS Hematocrit at inclusion NS Time from index bleeding (days) NS HVPG at inclusion (mm Hg) NS Mean arterial pressure (mm Hg) NS Cardiac output (L/min) NS Creatinine clearance (ml/min) NS BUN (mg/dl) NS A-II (pg/ml) NS ALD (ng/dl) NS NE (pg/ml) NS NOx (nmol/ml) NS ET (pg/ml) NS Dose after titration, median (range) (mg/day) 50 ( ) 50 ( ) HCV, hepatitis C virus; HBV, hepatitis B virus; BUN, blood ureic nitrogen; NE, norepinephrine; NOx, nitrates and nitrites; NS, not significant. A total of 25 patients were randomized to receive losartan and 15 propranolol. Three patients did not complete the study because of side effects in 1 patient receiving losartan and after withdrawal of consent in 2 patients (1 propranolol, 1 losartan). Thus, the final analysis includes 23 patients receiving losartan and 14 propranolol. The main characteristics of these patients are summarized in Table 1. There were no differences between patients randomized to losartan or propranolol in any parameter. Hepatic Hemodynamics Propranolol caused a significant reduction of HVPG ( 10% 11%, P 0.003) (Table 2). In contrast, HVPG was not significantly modified after long-term therapy with losartan ( 2% 12%, NS) (Table 2 and Figure 1). HVPG was unchanged by losartan in 12 patients, increased in 5, and decreased in 6 patients by more than 10%. These 6 patients included a high proportion of alcoholics (5 of 6 vs. 9 of 17 in nonresponders, P 0.2) and had a higher baseline HVPG ( vs mm Hg, P 0.02). The 5 alcoholics had withdrawn from alcohol before entering into the study, 3 of them less than 3 months before randomization. In the global series, the effects of losartan on HVPG were similar in alcoholics and nonalcoholics (alcoholics: from to ; nonalcoholics: from to mm Hg; NS). Similarly, among patients treated with propranolol, there were no significant differences in the changes in HVPG in alcoholics vs. nonalcoholics ( to mm Hg, vs to mm Hg; NS). In both treatment groups, changes in HVPG were similar in patients receiving or not receiving diuretics (data not shown). Hepatic blood flow was not modified by propranolol or losartan. AzBF was significantly reduced by propranolol, but not by losartan. Systemic Hemodynamics Propranolol decreased heart rate and CO and increased PAP, which were not modified by losartan (Table 2). MAP was not modified by propranolol, but signifi- Table 2. Splanchnic and Systemic Hemodynamics Before and After 6-Week Treatment With Losartan or Propranolol Losartan Propranolol Baseline 6 wk P Baseline 6 wk HVPG (mm Hg) NS HBF (L/min) NS NS AzBF (L/min) NS PAP (mm Hg) NS PCWP (mm Hg) NS NS MAP (mm Hg) NS CO (L/min) NS NS SVR (day sec 1 cm 5 ) HR (bpm) NS HBF, hepatic blood flow; AzBF, azygos blood flow; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedged pressure; HR, heart rate; NS, not significant. P
4 August 2001 LOSARTAN VS. PROPRANOLOL IN PORTAL HYPERTENSION 385 Figure 1. Changes in (A) HVPG and (B) MAP during long-term losartan or propranolol administration. Results are expressed as mean SEM. cantly decreased under losartan (Figures 1 and 2). Hypotension was caused by a decrease in peripheral resistance and was not correlated with changes in HVPG. The hypotensive effect of losartan was related to the degree of liver failure. MAP did not decrease in Child A Figure 2. Comparison of the effects of long-term administration of losartan ( ) or propranolol ( ) on splanchnic and systemic hemodynamics. Results are expressed as percent change from baseline study (mean SEM). a Significantly different from baseline; b significantly different from losartan. patients ( 2% 8%, NS), whereas Child B patients showed a significant fall in MAP and SVR (Table 3). Renal Function and Vasoactive Systems Baseline renal function and vasoactive factors were similar in patients receiving propranolol or losartan (Tables 1 and 3). Propranolol caused no changes in GFR, blood urea nitrogen, creatinine, sodium excretion, and vasoactive factors (data not shown). Losartan caused an effective blockade of A-II receptors, reflected by an increase in circulating A-II levels and a decrease in plasma ALD, which was observed both in Child A and Child B patients (Table 3). Sodium excretion, norepinephrine, NOx, and ET were not significantly modified by losartan. Child B patients had higher baseline levels of A-II, ALD, and ET than Child A patients. The reduction in MAP and SVR observed in Child B patients after losartan was associated with a significant decrease in GFR (Table 3). Intake of diuretics was not related with changes in GFR ( 7% 26% vs. 5% 33% in patients taking diuretics vs. those not taking diuretics; NS). Adverse Events The overall incidence of adverse events was similar in the propranolol (27%) and losartan (28%) group (Table 4). However, serious adverse events were more
5 386 GONZÁLEZ ABRALDES ET AL. GASTROENTEROLOGY Vol. 121, No. 2 Table 3. Effects of Losartan in Patients of Child A and B Class Child A (n 11) Child B (n 12) Basal 6 wk P Basal 6 wk P HVPG NS NS MAP NS SVR NS GFR NS Cr NS NS BUN NS NS U Na NS NS A-II a c 0.05 ALD a NE NS c NS NOx NS NS ET b NS c NS U Na, urinary sodium excretion; BUN, blood ureic nitrogen; Cr, creatinine; NE, norepinephrine; NS, not significant. a P 0.10 vs. baseline value in Child B patients. b P 0.05 vs. baseline values in Child B patients. c P 0.05 vs. 6-week value in Child A patients. common under losartan, including the 2 instances of rebleeding during the study period. None of the adverse events were lethal, and only 1 resulted in withdrawal. Discussion Portal hypertension is the result of increased hepatic resistance and portal inflow. 15 Splanchnic vasoconstrictors reduce portal pressure by decreasing portal inflow and have been the mainstay of pharmacologic therapy. 1 Recently, the recognition of a dynamic component in the increased hepatic resistance of cirrhosis 16 has led to the introduction of vasodilators in the treatment of portal hypertension. 17 Endogenous factors, such as endothelin, A-II, and alpha-adrenergic stimulus increase hepatic vascular resistance, 18,19 whereas it is decreased by endogenous vasodilators like NO 20 or CO. 21 Vasodilators, however, may cause arterial hypotension, which is undesirable because it enhances the activation of endogenous vasoactive systems and water and sodium retention. 6,7 Table 4. Side Effects of Treatment Losartan Propranolol Symptomatic 1 0 hypotension Fatigue 2 3 Increase in the 1 1 diuretic dose Variceal bleeding 2 0 Others 1 (urinary lithiasis) 0 Total, n 7 (28%) 4 (27%) NS Withdrawals 2 (1 fatigue, 1 withdrawn consent) 1 (withdrawn consent) A recent study reported a dramatic reduction of portal pressure in cirrhotic patients treated with losartan (a nonpeptide antagonist of A-II receptor type 1), 5 which has focused attention on A-II as a target in the treatment of portal hypertension. 9 Increased A-II is the result of the activation of the renin-angiotensin system (RAS), which is commonly observed in patients with cirrhosis and has been shown to correlate with HVPG. 22 Further, A-II increases hepatic resistance in isolated cirrhotic livers 18,19 and infusion of A-II increases portal pressure and decreases hepatic blood flow in patients with cirrhosis. 23 These effects are probably caused by the contraction of vascular smooth muscle cells as well as hepatic stellate cells. 24 Activation of RAS may also worsen portal hypertension as a result of increased liver fibrogenesis, which may worsen the evolution of cirrhosis. All the above suggest that preventing the activation of RAS, or blocking the activity of A-II, may have beneficial effects in decreasing portal pressure in cirrhosis. However, stimulation of RAS is thought to represent a homeostatic response to peripheral vasodilatation. 28 Therefore, there is a risk that interfering with RAS may enhance peripheral vasodilatation and arterial hypotension, with adverse consequences on renal function. Actually, the A-II receptor antagonist salarasin caused marked arterial hypotension in patients with cirrhosis and ascites. 8 Similar effects were reported with the angiotensin-converting enzyme inhibitor captopril. 29 The present randomized controlled trial was specifically designed to assess whether long-term losartan treatment may favorably influence portal hypertension in patients with cirrhosis without adverse effects on systemic hemodynamics and renal function. The effects of
6 August 2001 LOSARTAN VS. PROPRANOLOL IN PORTAL HYPERTENSION 387 losartan were compared with those of propranolol because this is the accepted therapy for portal hypertension that any new drug should be tested against. 1 Unfortunately, the results of the current study show that losartan does not reduce portal pressure in patients with cirrhosis, but causes arterial hypotension. This hypotensive effect was caused by peripheral vasodilatation and was marked enough to be associated with a significant reduction in GFR in patients with moderately impaired liver function (Child B) and increased A-II levels. Losartan did not cause hypotension in Child A patients and had no beneficial effect in HVPG. In contrast, propranolol significantly decreased portal pressure and gastroesophageal collateral blood flow, without any negative effect on arterial pressure and renal function. These results argue strongly against any potential for losartan (and probably for any other A-II blocker) in the treatment of portal hypertension. This is supported by the preliminary results reported using irbesartan. 30 Our findings are in disagreement with those of Schneider et al. 5 who reported a marked fall in HVPG after losartan, with only a mild (but significant) decrease in MAP. Actually, their reported decrease in HVPG represents the greatest reduction in portal pressure ever described with any drug. An explanation for such discrepant results is not obvious. The dose of losartan used in our study was not insufficient because it was higher than in the study by Schneider et al. 5 ; this dose (median, 50 mg) was chosen following the standard schedule used in arterial hypertension, the main indication for losartan. 31 The fact that losartan increased circulating A-II and decreased ALD and arterial pressure indicates an effective blockade of angiotensin receptors. The reason why we were unable to confirm a beneficial effect of losartan on HVPG is unclear. The possibility of false-negative results is extremely unlikely because the study had enough power according to published studies. 4,5 The risk of selection bias was minimized by including a homogeneous group of patients, who had all experienced (and recovered from) a variceal bleeding episode and were under endoscopic therapy, and more importantly, by having a randomized allocation to therapy using state-of-the-art techniques in clinical trials. To prevent observer bias, doctors following the patients were unaware of whether the patients were taking propranolol or losartan. Moreover, the reading of all HVPG tracings was done blindly by an experienced observer. On the other hand, time to response cannot be the issue because in the study by Schneider et al., changes in HVPG were already present at 1 week. Moreover, when looking at individual responses in HVPG, only 6 of our patients showed a decrease in HVPG of more than 10% of baseline after losartan. It is important to note that 5 of these 6 patients were alcoholics, as were most of the patients in the study by Schneider et al. This may suggest that alcoholics are prone to respond to losartan; however, changes in HVPG were not different in alcoholics and nonalcoholics. An alternative explanation is that the fall in HVPG may have been caused by withdrawing from alcohol, 32 which was indeed observed in our patients. The probability of inadvertent selection and/or observer bias in the study by Schneider et al., thus, exists. This occurred in a previous study by the same group, reporting that spironolactone decreases HVPG by 10 mm Hg, 33 a finding that was not confirmed subsequently. 34,35 Our results may suggest that the physiologic role of A-II regulating intrahepatic resistance is of little significance. This is probably true, at least in advanced stages of cirrhosis. The possibility that in early cirrhosis, blockade of A-II might decrease hepatic resistance and portal pressure cannot be excluded. In summary, unlike propranolol, long-term losartan administration does not significantly reduce HVPG in cirrhotic patients treated after a variceal bleeding episode. In addition, losartan causes arterial hypotension and reduces the GFR in patients with moderate liver failure. Therefore, losartan should not be used as an alternative to propranolol in preventing variceal rebleeding. References 1. D Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19: Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99: Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32: Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346: Schneider AW, Friedrich J, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29: Salmeron JM, Ruiz DA, Gines A, Garcia-Pagan JC, Gines P, Feu F, Claria J, Rivera F, Bosch J, Arroyo V. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993;17: Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, Iborra J, Garrido A, Escartin P, Bosch J. Continuous prazosin administration in cirrhotic patients: effects on portal
7 388 GONZÁLEZ ABRALDES ET AL. GASTROENTEROLOGY Vol. 121, No. 2 hemodynamics and on liver and renal function. Gastroenterology 1995;109: Arroyo V, Bosch J, Ribera F, Navarro-Lopez F, Rodes J. Effect of angiotensin-ii blockade on systemic and hepatic hemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981;11: Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology 1999;117: Bosch J, Groszmann RJ. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 1984;4: Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96: Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, Arroyo V, Piulats J, Rivera F, Rodes J. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 1993;18: Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodes J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28: Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, Mourelle M. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993;18: Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32: Bathal PS, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1: Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999;19: Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24: Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988;244: Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999;19: Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, Ishimura Y. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995;96: Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, Navarro- Lopez F, Rodes J. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: Segel N, Bayley TJ, Paton A, et al. The effects of synthetic vasopressin and angiotensin on the circulation in cirrhosis of the liver. Clin Sci 1963;25: Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118: Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000;118: McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98: Border WA, Noble NA. Interactions of transforming growth factorbeta and angiotensin II in renal fibrosis. Hypertension 1998;31: Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8: Alexandre Pariente E, Bataille C, Bercoff E, Lebrec D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985;88: Schepke M, Werner E, Bieker E, Schiedermaier P, Hofer U, Layer G, Heller J, Neef M, Sauerbruch T. The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: a placebo controlled, double blind study (abstr). Hepatology 2000; 32:406A. 31. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346: Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, Audano M, Tanno H, Lerner E, Passamonti M. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111: Klein CP. Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle? Dtsch Med Wochenschr 1985;110: Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19: Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23: Received February 6, Accepted April 11, Address requests for reprints to: Jaume Bosch, M.D., Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Villarroel 170, Barcelona, Spain. jbosch@medicina.ub.es; fax: (34) Supported in part by grants from Plan Nacional de Investigación y Desarrollo (SAF and SAF ) and Fondo de Investigaciones Sanitarias (FIS 00/0444); and an award from the Hospital Clinic, Barcelona (to J. G.-A.).
A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients
Annals of Hepatology 2003; 2(1): January-March: 36-40 Original Article Annals of Hepatology A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationPropranolol Plus Prazosin Compared With Propranolol Plus Isosorbide-5-mononitrate in the Treatment of Portal Hypertension
GASTROENTEROLOGY 1998;115:116 123 Propranolol Plus Prazosin Compared With Propranolol Plus Isosorbide-5-mononitrate in the Treatment of Portal Hypertension AGUSTÍN ALBILLOS,* JUAN CARLOS GARCÍA PAGÁN,
More informationCARLO MERKEL, MASSIMO BOLOGNESI, DAVID SACERDOTI, GIANCARLO BOMBONATO, BARBARA BELLINI, RAFFAELLA BIGHIN, AND ANGELO GATTA
The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis CARLO MERKEL, MASSIMO BOLOGNESI,
More informationHaemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis
Q J Med 1998; 91:19 25 Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis A.J. STANLEY, I. ROBINSON, E.H. FORREST, A.L. JONES and P.C. HAYES From the Department
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationHemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis
420 ORIGINAL ARTICLE July-August, Vol. 13 No. 4, 2014: 420-428 Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis Nancy Aguilar-Olivos,* Miguel
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationIs pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationPortal hypertension is the main complication of cirrhosis
GASTROENTEROLOGY 2001;120:726 748 Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis GUADALUPE GARCIA TSAO
More informationVariceal wall tension is thought to represent the key
Increasing Intra-abdominal Pressure Increases Pressure, Volume, and Wall Tension in Esophageal Varices Angels Escorsell, 1 Angels Ginès, 2 Josep Llach, 2 Joan C. García-Pagán, 1 Josep M. Bordas, 2 Jaume
More informationContinuous Prazosin Administration in Cirrhotic Patients: Effects on Portal Hemodynamics and on Liver and Renal Function
GASTROENTEROLOGY 1995;109:1257-1265 Continuous Prazosin Administration in Cirrhotic Patients: Effects on Portal Hemodynamics and on Liver and Renal Function AGUSTiN ALBILLOS,* JOSE LUIS LLEDO,* IRMA ROSSI,*
More informationS planchnic vasodilatation and increased portal blood flow is
259 LIVER The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis Agustín Albillos, Rafael Bañares, Mónica González, Maria-Vega Catalina,
More informationMeasurements of portal pressure have wide
Right Atrial Pressure Is Not Adequate to Calculate Portal Pressure Gradient in Cirrhosis: A Clinical-Hemodynamic Correlation Study Vincenzo La Mura, Juan G. Abraldes, Annalisa Berzigotti, Eva Erice, Alexandra
More informationWedged Hepatic Venous Pressure Adequately Reflects Portal Pressure in Hepatitis C Virus Related Cirrhosis
Wedged Hepatic Venous Pressure Adequately Reflects Portal Pressure in Hepatitis C Virus Related Cirrhosis ANTONIA PERELLÓ, 1 ÀNGELS ESCORSELL, 1 CONCEPCIÓ BRU, 2 ROSA GILABERT, 2 EDUARDO MOITINHO, 1 JUAN
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationBeta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)
Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol) Sharma BC, Gluud LL, Sarin SK This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationBeta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
The new england journal of medicine original article Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis Roberto J. Groszmann, M.D., Guadalupe Garcia-Tsao, M.D., Jaime Bosch, M.D.,
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationMEDICAL PROGRESS. Review Article. N Engl J Med, Vol. 345, No. 9 August 30,
Review Article Medical Progress GASTROESOPHAGEAL VARICEAL HEMORRHAGE ALA I. SHARARA, M.D., AND DON C. ROCKEY, M.D. GASTROESOPHAGEAL variceal hemorrhage, a major complication of portal hypertension resulting
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationNon-selective beta-blockers are the established
Influence of Beta-2 Adrenergic Receptor Gene Polymorphism on the Hemodynamic Response to Propranolol in Patients With Cirrhosis Juan Turnes, Manuel Hernández-Guerra, Juan G. Abraldes, Pau Bellot, Rafael
More informationNONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE UPDATES NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW Mihaela Dimache 1,2*, Irina Gîrleanu 1,2,
More informationThe current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding
Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding Salvador Augustin, 1 Antonio Gonzalez, 1 Laia Badia, 1 Laura Millan, 1 Aranzazu Gelabert, 2 Alejandro Romero,
More informationComplications of portal hypertension (PH) are
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION The Prognostic Value of Hepatic Venous Pressure Gradient in Patients With Cirrhosis Is Highly Dependent on the Accuracy of the Technique Gilberto Silva-Junior,
More informationHepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage
22 Vorobioff JD, et al., 2013; 12 (1): 22-29 CONCISE REVIEW January-February, Vol. 12 No.1, 2013: 22-29 Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationThe Value of Renal Artery Resistive Indices: Association with
The Value of Renal Artery Resistive Indices: Association with Esophageal Variceal Bleeding in Patients with Alcoholic Cirrhosis 1 Joo Nam Byun, M.D., Dong Hun Kim, M.D. Purpose: To determine whether resistive
More informationHemorragia por várices gastroesofágicas en la cirrosis
Hemorragia por várices gastroesofágicas en la cirrosis Referencias 1. Garcia-Tsao G, Sanyal AJ, Grace ND,Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases,
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationReview Article Pathophysiology of Portal Hypertension and Esophageal Varices
International Hepatology Volume 2012, Article ID 895787, 7 pages doi:10.1155/2012/895787 Review Article Pathophysiology of Portal Hypertension and Esophageal Varices Hitoshi Maruyama and Osamu Yokosuka
More informationAre the benefits of beta blockers in cirrhotics only related to decreased portal hypertension?
Editorial Page 1 of 5 Are the benefits of beta blockers in cirrhotics only related to decreased portal hypertension? Felix Piecha 1, Sebastian Mueller 2 1 Department of Medicine, University Medical Center
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationth Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26
44 th 44 th Annual AISF Meeting Rome, February 23 rd -26 th th, 2011 Update on the Baveno Consensus Conference Roberto de Franchis Department of of Clinical Sciences, University of of Milan, Head, Gastroenterology
More informationThe Effect of Valsartan, an Angiotensin II Receptor Antagonist, on Portal and Systemic Hemodynamics and on Renal Function in Liver Cirrhosis *
Effect of Valsartan in liver cirrhosis ORIGINAL PAPERS The Effect of Valsartan, an Angiotein II Receptor Antagonist, on Portal and Systemic Hemodynamics and on Renal Function in Liver Cirrhosis * Carmen
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationInvasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan
Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la
More informationIndications, results and benefits of the measurement of hepatic venous pressure gradient
Indications, results and benefits of the measurement of hepatic venous pressure gradient Poster No.: C-0976 Congress: ECR 2017 Type: Scientific Exhibit Authors: J. P. León Salinas 1, M. D. Ferrer-Puchol
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationTreatment of portal hypertension in the light of the Baveno VI Consensus Conference
r e v I E w A R T I C l e S Curierul medical, December 2015, Vol. 58, No 6 Treatment of portal hypertension in the light of the Baveno VI Consensus Conference E. Tcaciuc Department of Internal Medicine,
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Dilutional Hyponatremia in Patients With Cirrhosis and Ascites Almudena Porcel, MD; Fernando Díaz, MD, PhD; Paloma Rendón, MD; Manuel Macías, MD; Leopoldo Martín-Herrera, MD, PhD;
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationManagement of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP
Management of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP Variceal hemorrhage complicates cirrhosis in as many as 50% of patients and results in considerable morbidity and mortality.
More informationHaemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension
Gut, 1988, 29, 372-377 Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension D WSTABY, A GIMSON, P C HAYS, AND ROGR WILLIAMS From the Liver Unit, King's College School
More informationSupplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1
Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver
More informationClinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
More informationSubject Review. Pathophysiology and Treatment of Variceal Hemorrhage M.D., AND PATRICK S. KAMATH, M.D.
Subject Review Pathophysiology and Treatment of Variceal Hemorrhage LEWIS R. ROBERTS, M.D., AND PATRICK S. KAMATH, M.D. Portal hypertension results from increases in portal flow and portal vascular resistance.
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationHistological subclassification of cirrhosis based on histological haemodynamic correlation
Alimentary Pharmacology & Therapeutics Histological subclassification of cirrhosis based on histological haemodynamic correlation M. KUMAR*, P. SAKHUJA, A.KUMAR*,N.MANGLIK*,A.CHOUDHURY*,S.HISSAR*,A.RASTOGI
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationA. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017 Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016
More informationCase Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Thank you to Marika Rudler, Dominique Thabut, Adrian Gadano, and Jaime Bosch for
More informationINTRAVENOUS ALBUMIN IN PATIENTS WITH CIRRHOSIS AND SPONTANEOUS BACTERIAL PERITONITIS
EFFECT OF INTRAVENOUS ALBUMIN ON RENAL IMPAIRMENT AND MORTALITY IN PATIENTS WITH CIRRHOSIS AND SPONTANEOUS BACTERIAL PERITONITIS PAU SORT, M.D., MIQUEL NAVASA, M.D., VICENTE ARROYO, M.D., XAVIER ALDEGUER,
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationEmricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationT herapeutic (that is, total) paracentesis is used in patients
90 LIVER AND BILIARY DISEASE Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by : a randomised pilot study R Moreau, T
More informationPORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications
PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications Edy G. Trujillo, RN, MSN, ACNP-BC Liver Transplant RRUCLA Medical Center July 31, 2018 What Do We All Look Forward
More informationEarly Use of TIPS in Patients with Cirrhosis and Variceal Bleeding
The new england journal of medicine original article Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding Juan Carlos García-Pagán, M.D., Karel Caca, M.D., Christophe Bureau, M.D., Wim Laleman,
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationV ariceal haemorrhage is a major cause of mortality and
270 LIVER DISEASE The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric : clinical and haemodynamic correlations D Tripathi, G Therapondos, E
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationVariceal hemorrhage is a lethal complication of cirrhosis, particularly
T h e n e w e ngl a nd j o u r na l o f m e dic i n e review article Current Concepts Management of Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., and Jaime Bosch, M.D. Variceal
More informationSimvastatin Enhances Hepatic Nitric Oxide Production and Decreases the Hepatic Vascular Tone in Patients With Cirrhosis
GASTROENTEROLOGY 2004;126:749 755 Simvastatin Enhances Hepatic Nitric Oxide Production and Decreases the Hepatic Vascular Tone in Patients With Cirrhosis CARMEN ZAFRA, JUAN G. ABRALDES, JUAN TURNES, ANNALISA
More informationJMSCR Vol 04 Issue 08 Page August 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v4i8.23 Portal Hypertension in Adults- A Comprehensive
More informationPathophysiology, diagnosis and treatment of ascites in cirrhosis
Annals of hepatology 2002; 1(2): April-June: 72-79 Concise Review Annals of hepatology Pathophysiology, diagnosis and treatment of ascites in cirrhosis Vicente Arroyo 1, M.D. Abstract The mechanism by
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationHepatorenal syndrome
Annals of Hepatology 2003; 2(1): January-March: 23-29 Concise Review Annals of Hepatology Hepatorenal syndrome Andrés Cárdenas, M.D., 1 Vicente Arroyo, M.D. 2 Abstract Hepatorenal syndrome is complication
More informationPortal Hypertension in the 21st Century
Portal Hypertension in the 21st Century Portal Hypertension in the 21st Century Edited by R. J. Groszmann J. Bosch Yale University School of Medicine Hepatic Hemodynamic Laboratory New Haven, CT, Liver
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationINCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:689 695 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated
More informationPortal hypertension Guadalupe Garcia-Tsao, MD
Portal hypertension Guadalupe Garcia-Tsao, MD Portal hypertension, the main complication of cirrhosis, is responsible for its most common complications: variceal hemorrhage, ascites, and portosystemic
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationRenal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites
Nephrol Dial Transplant (2005) 20: 1623 1629 doi:10.1093/ndt/gfh871 Advance Access publication 10 May 2005 Original Article Renal effects of treatment with diuretics, octreotide or both, in non-azotemic
More informationMANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS
MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..
More informationIncidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;xx:xxx 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationHepatopulmonary Syndrome: An Update
Hepatopulmonary Syndrome: An Update Michael J. Krowka MD Professor of Medicine Division of Pulmonary and Critical Care Division of Gastroenterology and Hepatology Mayo Clinic Falk Liver Week October 11,
More informationClassification of cirrhosis: The clinical use of HVPG measurements
Disease Markers 31 (2011) 121 128 121 DOI 10.3233/DMA-2011-0834 IOS Press Classification of cirrhosis: The clinical use of HVPG measurements Agustín Albilllos a, and Guadalupe Garcia-Tsao b a Department
More informationTIPS. D Patch Royal Free Hospital London UK
TIPS D Patch Royal Free Hospital London UK TIPS Technique Ascites Budd Chiari Variceal Bleeding Historical Experimental Development 1967 Piccone Shunt between recanalized umbilical vein and saphenous
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More information